DDR1 has been overexpressed in multiple cancers such as non-small-cell lung carcinomas, pancreatic ductal adenocarcinoma, ovarian tumor, breast cancer, gastric cancer, endometrial tumors, glioblastoma, head and neck squamous cell carcinomas, esophageal carcinoma, cholangiocarcinoma, non-small-cell lung cancer, hepatocellular carcinoma, and prostate cancer. This evidence concerns the gene DDR1 and prostate carcinoma.